GLP-1 side effects and what TikTok gets wrong about them

What did @dremmaanders actually say?

The core argument here is that GLP-1 medications work differently depending on why someone has obesity in the first place. She says people who plateau aren't failing the drug, the drug is just not addressing their specific driver of weight gain. She specifically calls out neurodiversity as one underappreciated factor, and pushes back on the generic advice to "eat little and often," arguing that for some patients, larger, less frequent meals may actually be more appropriate. Her bottom line: stop following generic online advice and find a clinician who actually understands obesity as a medical condition, not a willpower problem.

Does the science back this up?

Mostly, yes, and this is one of the more scientifically honest GLP-1 takes you'll find on TikTok. The idea that obesity is heterogeneous, meaning it has multiple distinct biological and psychological subtypes, is well-supported in the literature. A 2021 paper by Spaethling et al. in Cell Metabolism and prior phenotyping work by Acosta et al. (2015, Gastroenterology) identified at least four distinct obesity phenotypes, including those driven by hedonic eating, impaired satiety, abnormal postprandial physiology, and emotional eating. GLP-1 receptor agonists primarily address impaired satiety and, to some degree, reward-driven eating. They do not directly target, for example, binge-eating patterns driven by ADHD-related impulsivity or sensory-seeking behavior in autistic individuals. Trials like STEP 1 (Wilding et al., 2021, NEJM) show dramatic average weight loss with semaglutide, but averages hide wide individual variation, something the media rarely acknowledges.

What did they get wrong (or right)?

The neurodiversity point is genuinely underappreciated and she deserves credit for raising it. ADHD, for instance, is associated with dysregulated dopamine signaling, impulsive eating, and difficulty with routine, none of which GLP-1s directly fix. A 2023 review by Cortese et al. in The Lancet Psychiatry noted that ADHD is significantly overrepresented in individuals with obesity, and that treating one without addressing the other often produces suboptimal outcomes.

Where the video is slightly imprecise is on the meal frequency claim. She says some patients need "a big meal to trigger fullness" and should eat fewer, larger meals. This isn't wrong for a specific phenotype, specifically the impaired satiety group, but presenting it as a general counter-principle risks overcorrecting. The existing evidence on meal frequency and weight management is genuinely mixed, and meal patterning should be individualized, not swapped for a new one-size-fits-all rule. To her credit, that's also exactly what she says. She's not recommending large meals for everyone, she's recommending personalization, which is the right call.

Her criticism of UK healthcare workers' understanding of obesity is fair but broad. NHS obesity training has historically been inadequate, though that is changing with updated NICE guidelines post-2023.

What should you actually know?

If you're on a GLP-1 and plateauing, the answer is not automatically "increase the dose." That's the lazy response, and it's not always the right one. The honest question is: what was driving your weight in the first place, and is this medication actually addressing that driver?

• GLP-1 receptor agonists primarily work by slowing gastric emptying and acting on hypothalamic satiety pathways. They don't directly treat compulsive eating driven by emotional dysregulation or neurodevelopmental conditions.
• ADHD affects an estimated 25-40% of people with obesity seeking treatment, per research by Pagoto et al. (2009, Obesity). If that's your driver, behavioral support and potentially ADHD treatment may matter more than titrating your semaglutide dose upward.
• The STEP trials showed that roughly 10-15% of participants lost less than 5% body weight on semaglutide, while others lost more than 20%. That spread is real, and it reflects biological heterogeneity, not inconsistency in the drug.
• Meal timing and frequency guidance should genuinely be individualized. If you feel better eating two or three larger meals and that allows you to experience fullness without grazing, that is a valid approach, but clear it with your prescribing clinician first.
• Finding a clinician who views obesity as a complex, multifactorial medical condition and not a character flaw is not a luxury. It is a clinical necessity if you want to use these medications effectively.

Is there anything missing from this video?

A few things. She doesn't mention the role of gut microbiome variability, sleep quality, or medication interactions, all of which can affect GLP-1 response. She also doesn't address the access problem: finding a clinician with genuine obesity medicine expertise is genuinely difficult in the UK and elsewhere, particularly outside private practice. Acknowledging that barrier would have made the advice more complete. Still, for a short-form video aimed at a general audience, this is a more nuanced and evidence-adjacent take than most of what circulates in the GLP-1 content space.